Louisiana State Employees Retirement System Has $4 Million Stake in Glaukos Co. (NYSE:GKOS)

Louisiana State Employees Retirement System increased its stake in Glaukos Co. (NYSE:GKOS) by 0.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,700 shares of the medical instruments supplier’s stock after acquiring an additional 100 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Glaukos were worth $4,003,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Glaukos by 294.5% in the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after acquiring an additional 1,630,270 shares in the last quarter. State Street Corp raised its position in shares of Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after purchasing an additional 98,109 shares during the period. Primecap Management Co. CA lifted its holdings in shares of Glaukos by 2.0% in the 3rd quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock worth $162,223,000 after purchasing an additional 24,370 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Glaukos by 6.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier’s stock worth $152,722,000 after purchasing an additional 66,134 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its position in Glaukos by 21.6% in the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier’s stock valued at $87,776,000 after purchasing an additional 119,527 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on GKOS shares. Truist Financial upped their price objective on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Wells Fargo & Company lifted their price objective on shares of Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. UBS Group initiated coverage on shares of Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective for the company. Piper Sandler reissued an “overweight” rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Finally, JPMorgan Chase & Co. boosted their price objective on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $151.08.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,328 shares of company stock valued at $2,289,521 over the last three months. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Down 1.1 %

GKOS opened at $143.80 on Thursday. Glaukos Co. has a 12 month low of $83.90 and a 12 month high of $163.71. The company has a 50 day moving average of $151.20 and a 200 day moving average of $137.79. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market cap of $7.93 billion, a PE ratio of -47.62 and a beta of 1.04.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.